Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983907 | 0.88 | KDM4E (0.60) | CYP1A2KDM4EDRD2DRD3HRH3 | |
| SCHEMBL4766909 | 0.87 | CYP1A2 (0.62) | CYP1A2KDM4EDRD2DRD3 | |
| SCHEMBL1474145 | 0.87 | PIM1 (0.49) | KDM4EDRD2DRD3HRH3 | |
| SCHEMBL1474114 | 0.84 | LTA4H (0.46) | CYP1A2KDM4EDRD2DRD3 | |
| SCHEMBL8249871 | 0.83 | GRM4 (0.45) | DRD2DRD3HRH3 | |
| SCHEMBL18591911 | 0.80 | MAOB (0.52) | KDM4E | |
| SCHEMBL18611964 | 0.80 | MAOB (0.52) | — | |
| SCHEMBL4441264 | 0.79 | HRH3 (0.61) | KDM4EDRD2DRD3HRH3 | |
| SCHEMBL445130 | 0.78 | KDM4E (0.55) | CYP1A2KDM4EDRD2DRD3 | |
| SCHEMBL9119332 | 0.77 | MAOB (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | CYP1A2 1743/4885KDM4E 2541/4885DRD2 2140/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | CYP1A2 1512/4885KDM4E 2528/4885DRD2 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.